What does Tesofensine do? Benefits and evidence

An oral appetite drug with weight-loss trial results and heart-rate and psychiatric risks.

Also called: NS2330, NS-2330, NS 2330.

Fat-loss drugs · Serotonin, norepinephrine and dopamine reuptake inhibitor.

Tesofensine is a small-molecule drug, not a peptide. Obesity trials found weight loss with daily oral doses. It has no FDA approval, and Mexican approval was not confirmed as of this review. Heart-rate increases and mental health effects are key concerns. The main 2008 trial later received an expression of concern about safety reporting.

  • A phase 2 trial reported weight loss, but its safety reporting raised concerns. (Studied in a trial)
  • A larger trial in Mexico also points to weight loss, though its full safety data were never published. (Studied in a trial)
  • In a study, people felt full sooner at first, but this faded with continued use. (Studied in a trial)
  • Some users report less appetite, and changes in mood, focus or motivation. (Reported by users)

Uses in the sources

  • A phase 2 obesity trial found more weight loss than placebo, but the journal later raised concerns about safety reporting. (Studied in a trial) (source)
  • Tesomet combines tesofensine with metoprolol. Small trials studied hypothalamic obesity, Prader–Willi syndrome and type 2 diabetes. (Studied in a trial) (source)
  • Alzheimer’s and Parkinson’s studies did not establish useful clinical benefit. (Studied in a trial) (source)
  • Some users report focus or mood effects. These are anecdotes, not evidence for ADHD or depression care. (Reported by users) (source)

Related to Tesofensine

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.